Feyman: FDA reforms, patent incentives can boost drug development

05/13/2014 | Forbes

Careful consideration of FDA regulatory reforms and current patent incentives is necessary to guarantee wider patient access to drugs and trigger more innovation, Yevgeniy Feyman writes. FDA regulation drives up the cost of drug development and effectively shortens the lives of drug patents, he writes. Creative solutions are needed that are sustainable to the pharmaceutical industry, payers and patients.

View Full Article in:

Forbes

Published in Brief: